**COVID-19 and Cancer Taskforce Global Modelling Consortium (CCGMC)**

**Model description for CCGMC WG2 (Impact on cancer screening and potential of ‘catch-up’ strategies for recovery)**

We are asking for this information only for planning purposes - because certain model types and levels of calibration/validation will be suitable for different types of collaborative analyses. For members that have model platforms that are still under development, please do complete the form to indicate this - and we expect that there will be opportunities to contribute to exploratory analyses. Please return this form to: [covidandcancer@nswcc.org.au](mailto:covidandcancer@nswcc.org.au)

# Model details:

|  |  |
| --- | --- |
| **Model name:** |  |
| **Has the model published in peer-reviewed journals? (please provide the main references for the model)** |  |
| **Applicable country/countries:** |  |
| **Current local cancer screening practice (screening technology, interval, and age range) simulated in the model:** |  |
| **Name and contact details of the model’s PI (s):** |  |

# Model descriptions

|  | **Y/N** | **Additional comments** |
| --- | --- | --- |
| *Demographic component:* | | |
| Is the model able to simulate dynamic populations (i.e. multiple birth cohorts) and not just a single cohort? |  |  |
| *Natural history component:* | | |
| Does the microsimulation model simulate the natural history of the precancer and cancer development (i.e. progression of precancer to cancer)? |  |  |
| Is cancer survival by cancer stage simulated? |  |  |
| *Cancer screening component:* | | |
| Is the model ready to simulate current local cancer screening practice (including screening test modality, screening interval, screening participation rate, follow-up diagnostic test compliance rate and screening test accuracy)? |  |  |
| Is the model flexible and able to simulate different cancer screening strategies that vary in screening test modality, screening interval, screening participation rate, follow-up diagnostic test compliance rate and screening test accuracy? |  |  |
| Is the model able to simulate variations in the impact of COVID-19 pandemic on cancer screening for different birth cohorts? |  |  |
| *Model calibration:* | | |
| Have model predictions for age-specific cancer incidence and mortality rates been calibrated to locally observed rates?  *Please provide calibration results (e.g. reference(s) to published results and/or additional documents with unpublished results)* |  |  |
| Have model predictions for age-specific prevalence of precancerous lesions been calibrated to locally observed prevalence?  *Please provide calibration results (e.g. reference(s) to published results and/or additional document with unpublished results)* |  |  |
| Please provide details of other model calibration results, including calibration relating to cancer screening (if any)  *Please provide calibration results (e.g. reference(s) to published results and/or additional document with unpublished results)* |  |  |
| *Model validation:* | | |
| Have model predictions been compared to other simulation models?  *Please provide validation results (e.g. reference(s) to published results and/or additional document with unpublished results)* |  |  |
| Has agreement between model findings and long-term follow-up findings of randomised-controlled trials that offered cancer screening been demonstrated?  *Please provide validation results (e.g. reference(s) to published results and/or additional document with unpublished results)* |  |  |

**Thank-you for completing this form. Any unpublished results sent with the form will be kept in confidence.**

**Please return this form to:** [**covidandcancer@nswcc.org.au**](mailto:covidandcancer@nswcc.org.au)